Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Design and development of a B7H3-targeting fluorescent probe for fluorescence-guided surgery of sarcoma

Award Number: R01CA317217
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

Design and development of a B7H3-targeting fluorescent probe for fluorescence-guided surgery of sarcoma - PROJECT SUMMARY Soft tissue sarcomas (STS) are mesenchymal cancers with >50 subtypes. Wide local excision (WLE)—removal of the primary tumor with a layer of non-cancerous tissue surrounding it—is required for curative local control. However, surgeons fail to achieve WLE in up to 34% of patients, with recurrence occurring in nearly half of these patients and negative survival effects. Thus, intraoperative recognition of positive margins and immediate removal of residual STS would significantly improve outcomes for patients with STS. Fluorescence-guided surgery—paired with cancer-targeted optical probes—have enabled real-time intraoperative cancer identification, tumor margin assessment, and removal of residual disease. FGS efficacy is optimized when contrast agents have high tumor-to-background contrast. On-going clinical trials with existing agents targeting the epidermal growth factor (EGFR) have demonstrated feasibility for FGS in STS, but results were underwhelming due to inconsistent EGFR expression between patients and intratumoral EGFR heterogeneity. More recent human data demonstrates high expression of the transmembrane protein B7-H3, an immune checkpoint protein, in STS. Antibodies targeting B7-H3, such as enoblituzumab (MGA271), are being investigated as therapeutics towards B7-H3-expressing solid tumors. In a collaborative effort, we conjugated MGA271 to IRDye800 and deployed the resulting compound in our established rodent models of human STS xenografts; contrast and tumor specificity results are promising. Our team has extensive experience in developing targeted fluorescence imaging agents for FGS, including STSs. Herein, we will expand the development of B7-H3-targeting antibody-fluorophore conjugates. We believe these conjugates will be strong candidates for preclinical development due to consistent B7-H3 expression in STS and the availability of mAbs targeting B7-H3 in clinical trials. We hypothesize that NIR fluorophore-antiB7-H3 mAb conjugates will bind to B7- H3-overexpressing STSs and provide strong contrast enhancement to guide surgical resection. Therefore, the goal of this proposal is to perform a thorough preclinical evaluation of NIR fluorescent conjugates of B7- H3-targeting antibodies for FGS of STS. This goal will be addressed by three specific aims: (1) To develop fluorescence-guided surgery probes that target B7-H3 using antibody-derived targeting ligands; (2) To establish the safety and in vivo dynamics of fluorescently labelled B7-H3-targeting agents; and (3) To evaluate the preclinical surgical efficacy of fluorescently-labelled B7-H3 targeting agents in orthotopic models of sarcoma. Animal models are required due to the complexity of factors affecting tumor and tissue/organ accumulation of contrast agents and to evaluate the complex factors of FGS for surgical oncology. Completion of this research project will produce FGS contrast agents that detect and guide removal of STS and accomplish a pivotal step towards future clinical development of a targeted probe for FGS of STS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $577,854 )
2026	2026	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	4215 EMILE ST	OMAHA	NE	68105	DOUGLAS	USA	Cancer Detection and Diagnosis Research	000	1	7/28/2026	NEW	$577,854
														Subtotal = $577,854

Grand Total All Awards = $577,854

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Design and development of a B7H3-targeting fluorescent probe for fluorescence-guided surgery of sarcoma

Award Number: R01CA317217

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer